Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Dose Optimization vs Nilotinib in CML with Suboptimal Response to Standard-Dose Imatinib
2008-007054-35Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in chronic myelogenous leukemia (CML) comparing Imatinib dose optimization with Nilotinib (2 arms). Primary endpoint: Complete cytogenetic response at 6 months. Started Jun 2009; status: completed.
02
Drugs
nilotinibimatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2008-007054-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007054-35.